| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/26/2006 | US20060019935 Composition and method for treating acne including anti-inflammatory Hepes Oleate |
| 01/26/2006 | US20060019934 Anti-HIV-1 activity of betulinol derivatives |
| 01/26/2006 | US20060019933 Process for preparing stabilized vitamin D |
| 01/26/2006 | US20060019932 Treatment of rheumatoid arthritis by inhibition of pde4 |
| 01/26/2006 | US20060019931 Treating bone-related disorders with selective androgen receptor modulators |
| 01/26/2006 | US20060019930 Treatment and prevention of tissue damage |
| 01/26/2006 | US20060019929 Combination therapies employing platelet aggregation drugs |
| 01/26/2006 | US20060019928 (Hetero)arylamino-substituted tricyclic pyrrolopyrrolotriazine compounds, used for treating adult respiratory distress syndrome, chronic obstructive pulmonary disease, chronic pulmonary inflammatory disease, solid organ transplant rejection, atherosclerosis, and arthritis |
| 01/26/2006 | US20060019927 Anti-viral uses of borinic acid complexes |
| 01/26/2006 | US20060019926 Using dextran, or derivative thereof |
| 01/26/2006 | US20060019925 Peritoneal dialysis method |
| 01/26/2006 | US20060019918 Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides |
| 01/26/2006 | US20060019910 Inhibiting c Jun amino terminal kinase signal transduction pathway; reducing tumor necrosis factor alpha induced lipolysis |
| 01/26/2006 | US20060019908 Process for the preparation of azithromycin monohydrate isopropanol clathrate |
| 01/26/2006 | US20060019907 Guggulsterone: an inhibitor of nuclear factor - kappaB and IkappaBalpha kinase activation and uses thereof |
| 01/26/2006 | US20060019906 Useful as an anti-HIV agent that particularly shows an anti-HIV action based on an integrase inhibitory activity; for treatment or prophylaxis of AIDS; for example, 6-(2,3-dichlorobenzyl)-1-(2-hydroxyethyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid |
| 01/26/2006 | US20060019888 such as viral myocarditis (Coxsackie virus, echovirus, polio virus) or dilated (congestive) cardiomyopathy, by binding ErbB2-ErbB4 receptors; atpase inhibitors |
| 01/26/2006 | US20060019887 Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer |
| 01/26/2006 | US20060019883 Use of cyclin D1 inhibitors |
| 01/26/2006 | US20060019876 Targeted delivery of bioaffecting compounds for the treatment of cancer |
| 01/26/2006 | US20060019872 Oral formulations for poorly absorptive hydrophilic drugs |
| 01/26/2006 | US20060019870 Apoprotein cochleate compositions |
| 01/26/2006 | US20060019868 Biocompatible liquid, biocompatible gas, and solid particles of a biocompatible polymer are mixed together to form a homogenous composition including a discontinuous gas phase with solid particles homogenously dispersed throughout a continuous liquid phase |
| 01/26/2006 | US20060019392 Novel bone mineralization proteins, DNA, vectors, expression systems |
| 01/26/2006 | US20060019383 Chemical inhibitors of mismatch repair |
| 01/26/2006 | US20060019371 Macrolide analogs |
| 01/26/2006 | US20060019269 Peripheral arterial occlusive disease (PAOD); prophylaxis of myocardial infarction by administering an agent that inhibits leukotriene synthesis in vivo for example (R)-(+)-alpha-cyclopentyl-4-(2-quinolinylmethoxy)-Benzeneacetic acid, BAY-X-1005; coadministering a statin |
| 01/26/2006 | US20060019246 Synthetic C-glycolipid and its use for treating cancer, infectious diseases, and autoimmune diseases |
| 01/26/2006 | US20060019240 Posh nucleic acids, polypeptides and related methods |
| 01/26/2006 | US20060019239 enhancing the immunogenicity of a vaccine against Bacillus anthracis by administering an oligodeoxynucleotide with a vaccine against Bacillus anthracis; Anthrax Vaccine Adsorbed (AVA) vaccine |
| 01/26/2006 | US20060018983 Composition containing green-yellow vegetables and light-colored vegetables |
| 01/26/2006 | US20060018975 Methods and compositions for weight management and mood enhancement |
| 01/26/2006 | US20060018973 Composition for stimulating bone-formation and bone consolidation |
| 01/26/2006 | US20060018972 Aqueous sustained-release drug delivery system for highly water-soluble electrolytic drugs |
| 01/26/2006 | US20060018970 Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure |
| 01/26/2006 | US20060018966 Antimicrobial mesoporous silica nanoparticles |
| 01/26/2006 | US20060018962 Sustained release formulation of tramadol |
| 01/26/2006 | US20060018961 Compression formed preparation and method for manufacturing same |
| 01/26/2006 | US20060018960 solid oral dosage form comprising about 83 to 332 mg of aliskiren or a hemi-fumarate salt thereof; in vitro dissolution profile of more than 46% by weight of the oral dosage form; renin inhibitor; antihypertensives for treating congestive heart failure; industrial scale manufacture |
| 01/26/2006 | US20060018959 Solid drug for oral use |
| 01/26/2006 | US20060018958 Soft gel formulation includes Coenzyme Q10, Vitamin E, beta-carotene, bee's wax, medium chain triglycerides available as MCT Myglyol S12, and rice bran oil formulated to maximize the body's absorption |
| 01/26/2006 | US20060018956 Dermal application system for aminolevulinic acid-derivatives |
| 01/26/2006 | US20060018955 Method for preparing medical dressings |
| 01/26/2006 | US20060018946 such as temporomandibular joint disorders, osteoarthritis of the knee, hip and other types of inflammatory joint diseases; identifying specific matrix metalloproteinase; and injecting a polymer gel with the component the MMP(s) seek to destroy, thus preserving the joint and allowing time to heal |
| 01/26/2006 | US20060018944 Alternating layers of a polycationic polyelectrolyte, Polyarginine and a polyanionic polyelectrolyte, heparin coated on a stent in vivo; drug delivery; sustained release; side effect reduction; preventing retenosis,vulnerable plaque |
| 01/26/2006 | US20060018937 Container containing pressurized product; mixture of water, hydrophobic solvent, surfactant,gellation agent; oil in water emulsions |
| 01/26/2006 | US20060018933 Novel drug delivery system |
| 01/26/2006 | US20060018930 Compositions comprising viruses and methods for concentrating virus preparations |
| 01/26/2006 | US20060018926 Noscapine derivatives as adjuvant compositions and methods of use thereof |
| 01/26/2006 | US20060018924 Recombinantly produced, enzymatically active, includes two amino acid motifs |
| 01/26/2006 | US20060018921 Histone deacetylase inhibitors and cognitive applications |
| 01/26/2006 | US20060018915 Heteroclitic analogs and related methods |
| 01/26/2006 | US20060018910 Administering anti-insulin-like growth factor I receptor (IGF-1R) antibodies to treat advanced non-small cell lung cancer |
| 01/26/2006 | US20060018904 Combination therapies utilizing benzamide inhibitors of the P2X7 receptor |
| 01/26/2006 | US20060018898 Antibody variants |
| 01/26/2006 | US20060018895 Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof |
| 01/26/2006 | US20060018894 Administration of enoxoparin sodium to patients 75 years and older with ST-segment elevation myocardial infarction |
| 01/26/2006 | US20060018893 Method for determining modulation of P110delta activity |
| 01/26/2006 | US20060018891 Soft gel capsule, beta-carotene; vitamin E; yellow beeswax;a mixture of mono-, di, tri-glycerides of 16 to 18 carbon chain length and polyglycerol oleate; rice bran oil |
| 01/26/2006 | US20060018884 Method for treating human tumor cells with a newcastle disease virus strain and a chemotherapeutic agent |
| 01/26/2006 | US20060018881 Coordinate in vivo gene expression |
| 01/26/2006 | US20060018876 Treatment of diseases caused by viral infection |
| 01/26/2006 | US20060018872 Poly(lactic acid) copolymer hydrogels and related methods of drug delivery |
| 01/26/2006 | US20060018870 Rigid polymer and method of making same |
| 01/26/2006 | US20060018862 Substrate based skin care device |
| 01/26/2006 | US20060018861 Skin care composition |
| 01/26/2006 | US20060018860 Skin care composition |
| 01/26/2006 | US20060018858 Skin care composition |
| 01/26/2006 | US20060018852 cosmetic and dermatological compositions containing hydrocortisone, a glycol and a thickening or gelling agent; chemical stability |
| 01/26/2006 | US20060018847 Active ingredient combinations of polyhexamethylenebiguanidine hydrochloride and distearyldimethylammonium chloride and preparations comprising said active ingredient combinations |
| 01/26/2006 | US20060018840 Aerosolizable formulation comprising nicotine |
| 01/26/2006 | US20060018839 Synergistic atorvastatin or atorvastsin calcium and donepezil or donepezil hydrochloride administered seperately or concurrently; nasal dosage forms; Alzheimer's Disease |
| 01/26/2006 | US20060018837 Pharmaceutical compositions and methods for the prevention of drug misuse |
| 01/26/2006 | US20060018827 Positron therapy of inflammation, infection and disease |
| 01/26/2006 | US20060018826 Biologic modulations with nanoparticles |
| 01/26/2006 | US20060018825 Probe for diseases with amyloid accumulation, amyloid-staining agent, remedy and preventive for diseases with amyloid accumulation and diagnostic probe and staining agent for neurofibrillary change |
| 01/26/2006 | DE202005016250U1 Topiramat und pharmazeutische Formulierungen davon Topiramate and pharmaceutical formulations thereof |
| 01/26/2006 | DE19938668B4 Tränenersatzmittel Artificial tears |
| 01/26/2006 | DE102004032711A1 Substituierte Hydroxyacetophenonderivate Substituted hydroxyacetophenone |
| 01/26/2006 | DE102004032674A1 Neue 2-substituierte Estra-1,3,5(10)-trien-17-one als Inhibitoren der 17β-Hydroxysteroiddehydrogenase Typ 1 New 2-substituted estra-1,3,5 (10) triene-17-one 17β-hydroxysteroid dehydrogenase inhibitors of type 1 |
| 01/26/2006 | DE102004032673A1 Neue 2-substituierte D-Homo-estra-1,3,5(10)-triene als Inhibitoren der 17ß-Hydroxysteroiddehydrogenase Typ 1 New 2-substituted D-homo-estra-1,3,5 (10) -trienes 17beta-hydroxysteroid dehydrogenase inhibitors of type 1 |
| 01/26/2006 | DE102004031850A1 Substituirte Tetrahydroisochinoline als MMP-Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament Substituirte tetrahydroisoquinolines as MMP inhibitors, to processes for their preparation and their use as a medicament |
| 01/26/2006 | DE102004030409A1 Neue Verwendung von Meloxicam in der Veterinärmedizin Novel use of meloxicam in veterinary medicine |
| 01/26/2006 | CA2833770A1 Oxidative degradation products of atorvastatin calcium |
| 01/26/2006 | CA2615966A1 Hydrating composition |
| 01/26/2006 | CA2581155A1 Treatment of burns |
| 01/26/2006 | CA2581068A1 Treatment of tumours |
| 01/26/2006 | CA2579724A1 Amino-5,5-diphenylimidazolone derivatives for the inhibition of beta-secretase |
| 01/26/2006 | CA2578600A1 Diphenylimidazopyrimidine and -imidazole amines as inhibitors of b-secretase |
| 01/26/2006 | CA2574766A1 Estrogen receptor modulators |
| 01/26/2006 | CA2574475A1 Indolone derivatives, processes for preparing them and their uses |
| 01/26/2006 | CA2574464A1 Substituted quinolones |
| 01/26/2006 | CA2574423A1 Preparation for use of aspartate and vitamin b12 or biotin for regulating ketone bodies |
| 01/26/2006 | CA2574381A1 Composition comprising protein material and non-oxidizable fatty acid entities |
| 01/26/2006 | CA2574366A1 Composition comprising plant and/or fish oils and compounds comprising non-oxidizable fatty acid entities |
| 01/26/2006 | CA2574359A1 Arylacetic acids and related compounds for treatment of alzheimer's disease |
| 01/26/2006 | CA2574354A1 Imidazole and thiazole derivatives as antiviral agents |
| 01/26/2006 | CA2574237A1 Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof |
| 01/26/2006 | CA2574232A1 Use of compounds containing thiol groups as an efflux pump inhibitor |
| 01/26/2006 | CA2574204A1 Fused pyrimidones useful in the treatment and the prevention of cancer |